InvestorsHub Logo
Followers 5
Posts 207
Boards Moderated 0
Alias Born 02/14/2021

Re: boi568 post# 383952

Friday, 11/18/2022 7:17:59 AM

Friday, November 18, 2022 7:17:59 AM

Post# of 459304
https://www.biospace.com/article/releases/cortexyme-s-atuzaginstat-slowed-cognitive-decline-in-participants-with-alzheimer-s-disease-and-p-gingivalis-infection-in-phase-2-3-gain-trial-additional-top-line-data-presented-at-ctad-2021/

https://ir.quincetx.com/news-releases/news-release-details/cortexyme-present-results-gain-trial-phase-23-study-atuzaginstat

https://ir.quincetx.com/news-releases/news-release-details/cortexyme-reports-gain-trial-data-demonstrated-relationship

While I’m hopeful results will be good and happy that I’ve been invested in AVXL since 2014, I don’t agree that a press release announcing a company will present its results in the oral late breaking portion of CTAD means results will be good. This company’s results failed to meet endpoints. Also, their results were also published in a journal.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News